|  | Cancer | Lymphoma

Follicular Lymphoma Treatment Planning: 10 Key Decision Factors

Follicular lymphoma (FL) is indolent but heterogeneous. Treatment planning balances disease control, toxicity, and quality of life.

Decision Framework

  1. Histologic Grade & Stage: Grade 1–2 (indolent) vs. 3A/3B (aggressive). Ann Arbor stage (I–IV) + bulk. PET-CT for staging.
  2. Patient Factors: Age, ECOG, comorbidities (CIRS), renal/hepatic function, frailty.
  3. Symptom Burden & Disease Tempo: "GELF" criteria (nodes >7cm, ≥3 nodes >3cm, B-symptoms, splenomegaly, effusions, cytopenias, symptomatic progression) trigger treatment.
  4. Treatment Goals: Cure (rare, early stage RT), long-term control, symptom relief, QoL preservation.
  5. Therapeutic Options:
    • Early stage (I–II): Involved-site RT (curative intent).
    • Advanced asymptomatic: Watch & Wait (standard).
    • Advanced symptomatic: R-chemo (R-Benda, R-CHOP, R-CVP) → R-maintenance × 2y.
    • Relapsed: EZH2i (tazemetostat), PI3Ki (leniolisib — APDS), BTKi (zanubrutinib), CAR-T (3L+), Bispecifics (mosunetuzumab, epcoritamab), Len + R².
  6. Biomarkers: EZH2 mutation (tazemetostat response), POD24 (progression <24 mo post-R-chemo = high risk), m7-FLIPI.
  7. Toxicity Profiles: Match to comorbidities (e.g., avoid PI3Ki if colitis/pneumonitis history; BTKi if AFib/bleeding risk).
  8. Patient Values: Oral vs. IV; fixed vs. continuous; travel burden; fertility preservation.
  9. Cost & Access: Oral oncolytic parity; specialty pharmacy; trial access.
  10. Surveillance Plan: q3–6mo visits, labs, imaging (CT/PET per risk); POD24 vigilance.
  11. Psychosocial Support: FL is chronic; anxiety/depression common; integrate palliative care early.

Shared Decision-Making

Use decision aids (Lymphoma Coalition, NCCN). Document goals-of-care conversation. Revisit at each transition.

Lymphoma - Related Articles